Uncategorized

Biomarkers have become indispensable tools in toxicology and drug safety assessment, providing measurable indicators of biological processes, pathogenic responses, or pharmacologic effects. Their use enhances the sensitivity and specificity of toxicity detection, facilitates early identification of adverse effects, and supports mechanistic understanding of drug action. Biomarkers can be classified into several types: diagnostic, prognostic, predictive,…

Regulatory guidelines for preclinical toxicology establish the framework and standards to ensure that nonclinical safety studies are scientifically valid, reliable, and acceptable to regulatory authorities worldwide. These guidelines provide critical directions for the design, conduct, and reporting of toxicology studies supporting Investigational New Drug (IND) applications and New Drug Applications (NDA). International bodies such as…

Pharmacodynamics (PD) is a fundamental aspect of preclinical research that focuses on understanding the biochemical, molecular, and physiological effects of drugs on living organisms. It addresses how a drug interacts with its biological target and the subsequent cellular and systemic responses. These studies provide critical insight into a drug’s mechanism of action, efficacy, and safety,…

Good Laboratory Practice (GLP) compliance is essential for preclinical toxicology studies to ensure data integrity, reproducibility, and regulatory acceptance. GLP standards provide a structured framework covering study planning, conduct, data collection, reporting, and quality assurance. Designing a GLP-compliant study begins with a clear statement of objectives, including selection of relevant animal species, dose levels, and…

Histopathology is a cornerstone of preclinical toxicology studies, providing detailed microscopic analysis of tissue architecture and cellular morphology to detect and characterize adverse effects caused by investigational compounds. Unlike biochemical assays or molecular biomarkers that offer indirect evidence of toxicity, histopathology delivers direct visualization of tissue damage, inflammation, degeneration, and repair processes, making it indispensable…

Pharmacokinetics (PK) and toxicokinetics (TK) are critical components of drug development, providing quantitative data on the absorption, distribution, metabolism, and excretion (ADME) of compounds, as well as their concentration–time profiles related to toxic effects. Understanding PK and TK helps optimize dosing regimens, predict human responses, and assess safety margins. Pharmacokinetic studies focus on characterizing drug…

The pursuit of alternatives to animal testing in toxicology has gained significant momentum, driven by ethical considerations, regulatory encouragement, and technological advancements. In vitro methods provide controlled, reproducible platforms to evaluate toxicity while reducing animal use, costs, and study durations. Cell-based assays using primary cells, immortalized cell lines, or stem cell–derived differentiated cells allow assessment…

Biomarkers have become indispensable tools in preclinical toxicology, serving as measurable indicators that reflect biological processes, pharmacologic responses, or toxic effects induced by investigational compounds. Their application spans early drug development to regulatory submissions, enhancing the sensitivity, specificity, and mechanistic understanding of toxicity assessments. In preclinical settings, biomarkers are broadly categorized into exposure biomarkers, effect…

RNA-based therapeutics, including siRNA, antisense oligonucleotides (ASOs), and mRNA vaccines, offer precise modulation of gene expression but also present unique challenges related to off-target effects. These unintended interactions can lead to toxicity, immune activation, or altered expression of non-target genes, complicating preclinical safety assessments. In vitro screening using transcriptomic and proteomic profiling helps identify off-target…

Omics technologies—encompassing genomics, transcriptomics, proteomics, metabolomics, and epigenomics—have transformed toxicology by enabling comprehensive molecular profiling of biological responses to chemical or pharmaceutical exposures. These high-throughput platforms facilitate mechanism-based toxicology by identifying early molecular signatures of toxicity, elucidating affected biological pathways, and uncovering potential biomarkers for safety assessment. Transcriptomics, especially through RNA sequencing (RNA-seq), allows for…